Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD51 | Q06609 | 1/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 8/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | TNKS | O95271 | 1/20 | 0.44 |
| ▸ | GUSB | P08236 | 1/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.44 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.44 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22449437 | 0.86 | CFTR (0.41) | CFTRMAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL17620557 | 0.85 | KDM4E (0.40) | RAD51MAPTALDH1A1SMN1; SMN2HTT | |
| SCHEMBL17634380 | 0.83 | ALDH1A1 (0.49) | CFTRMAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL17620574 | 0.82 | ALDH1A1 (0.51) | RAD51CFTRMAPTKMT2AALDH1A1 | |
| SCHEMBL22449433 | 0.82 | MEN1 (0.49) | RAD51KMT2AALDH1A1MEN1TNKS | |
| SCHEMBL21656455 | 0.82 | RAD51 (0.38) | RAD51MAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL22449438 | 0.82 | RAD51 (0.50) | RAD51MAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL17620569 | 0.82 | CYP19A1 (0.47) | RAD51KMT2AALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL17620578 | 0.82 | TDP1 (0.49) | MAPTALDH1A1SMN1; SMN2KDM4EL3MBTL1 | |
| SCHEMBL17620587 | 0.82 | KDM4E (0.49) | KMT2AALDH1A1MEN1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787448-B2 | Indolizino [3,2-C] quinoline-based fluorescent probe | SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION (KR) | 2020-09-29 | — | — | US | disclosed |
| WO-2017014601-A1 | INDOLIZINO [3,2-C] QUINOLINE-BASED FLUORESCENT PROBE | 서울대학교 산학협력단 | 2017-01-26 | — | — | WO | disclosed |
| US-20160108042-A1 | INDOLIZINO[3,2-c]QUINOLINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CYSTIC FIBROSIS CONTAINING THE SAME AS ACTIVE INGREDIENT | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2016-04-21 | — | — | US | disclosed |
| US-20160108042-A1 | INDOLIZINO[3,2-c]QUINOLINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CYSTIC FIBROSIS CONTAINING THE SAME AS ACTIVE INGREDIENT | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2016-04-21 | — | — | US | disclosed |
| US-20160108042-A1 | INDOLIZINO[3,2-c]QUINOLINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CYSTIC FIBROSIS CONTAINING THE SAME AS ACTIVE INGREDIENT | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2016-04-21 | — | — | US | disclosed |
| US-9296751-B1 | Indolizino[3,2-c]quinoline derivatives, pharmaceutically acceptable salt thereof, preparation method thereof and pharmaceutical composition for treatment of cystic fibrosis containing the same as active ingredient | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2016-03-29 | — | — | US | disclosed |
| US-9296751-B1 | Indolizino[3,2-c]quinoline derivatives, pharmaceutically acceptable salt thereof, preparation method thereof and pharmaceutical composition for treatment of cystic fibrosis containing the same as active ingredient | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2016-03-29 | — | — | US | disclosed |
| US-9296751-B1 | Indolizino[3,2-c]quinoline derivatives, pharmaceutically acceptable salt thereof, preparation method thereof and pharmaceutical composition for treatment of cystic fibrosis containing the same as active ingredient | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2016-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787448-B2 | Indolizino [3,2-C] quinoline-based fluorescent probe | DNA2, IRF3, DDB1 | RAD51 1360/4885CFTR 4126/4885MAPT 1031/4885 |
| US-20160108042-A1 | INDOLIZINO[3,2-c]QUINOLINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CYSTIC FIBROSIS CONTAINING THE SAME AS ACTIVE INGREDIENT | CFTR, AQP3, AQP1 | RAD51 4838/4885CFTR 1/4885MAPT 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.